CVS Health (NYSE:CVS) Rating Increased to Buy at Wall Street Zen

Posted by John Perry on Jul 24th, 2026

Wall Street Zen upgraded shares of CVS Health (NYSE:CVS – Free Report) from a hold rating to a buy rating in a research report sent to investors on Thursday.

Several other brokerages also recently issued reports on CVS. Truist Financial boosted their price target on shares of CVS Health from $108.00 to $118.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Deutsche Bank Aktiengesellschaft upped their target price on shares of CVS Health from $88.00 to $92.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Royal Bank Of Canada boosted their price objective on CVS Health from $107.00 to $113.00 and gave the stock an “outperform” rating in a research report on Thursday, July 9th. Weiss Ratings raised shares of CVS Health from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday. Finally, Mizuho boosted their price target on shares of CVS Health from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. Twenty-one research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $105.38.

Read Our Latest Stock Report on CVS

CVS Health Price Performance

Shares of NYSE:CVS opened at $106.86 on Thursday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. The firm has a 50-day simple moving average of $99.98 and a 200 day simple moving average of $85.97. CVS Health has a fifty-two week low of $58.50 and a fifty-two week high of $110.68. The company has a market cap of $136.35 billion, a PE ratio of 47.08, a P/E/G ratio of 1.06 and a beta of 0.61.

CVS Health (NYSE:CVS – Get Free Report) last posted its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. During the same period in the prior year, the company earned $2.25 earnings per share. The business’s revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, sell-side analysts anticipate that CVS Health will post 7.46 EPS for the current year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 23rd will be issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Thursday, July 23rd. CVS Health’s payout ratio is presently 117.18%.

Insider Activity

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the sale, the executive vice president directly owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This represents a 87.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Larry Robbins sold 370,462 shares of CVS Health stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the transaction, the director directly owned 4,824,799 shares in the company, valued at $450,877,466.55. This represents a 7.13% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Trust Asset Management LLC boosted its stake in shares of CVS Health by 1.1% during the 2nd quarter. Trust Asset Management LLC now owns 14,171 shares of the pharmacy operator’s stock worth $1,466,000 after acquiring an additional 149 shares in the last quarter. Walker Asset Management LLC acquired a new stake in shares of CVS Health during the second quarter worth $207,000. Regent Peak Wealth Advisors LLC purchased a new stake in shares of CVS Health during the second quarter valued at $253,000. Annex Advisory Services LLC lifted its holdings in shares of CVS Health by 5.7% during the second quarter. Annex Advisory Services LLC now owns 6,867 shares of the pharmacy operator’s stock valued at $710,000 after purchasing an additional 368 shares during the last quarter. Finally, Tema ETFs LLC boosted its position in shares of CVS Health by 10.5% in the 2nd quarter. Tema ETFs LLC now owns 22,903 shares of the pharmacy operator’s stock valued at $2,369,000 after purchasing an additional 2,175 shares during the period. Institutional investors own 80.66% of the company’s stock.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

Positive Sentiment: Analysts and market commentary pointed to improving execution, stronger payer margins, and a modest lift in CVS’s fair value estimate, suggesting Wall Street sees more upside in the stock. CVS Health (CVS) Stock Sees Modest Fair Value Lift As Analysts Raise Targets
Positive Sentiment: Options activity was unusually strong, with traders buying far more call options than normal, which can signal expectations for continued upside.
Positive Sentiment: CVS’s new nationwide pet-prescription service has generated widespread coverage and could support pharmacy traffic and customer engagement. CVS is making it easier for pet owners with a new perk
Neutral Sentiment: Brokerage coverage remains constructive, with CVS receiving a consensus “Moderate Buy” rating and another recent upgrade to Buy, reinforcing a generally favorable analyst stance. CVS Health Corporation (NYSE:CVS) Receives Consensus Rating of “Moderate Buy” from Brokerages
Neutral Sentiment: Several articles highlighted CVS’s community-health investments in Massachusetts, but these are more reputational than immediately material to earnings. CVS Health Helping to Strengthen Communities Across Massachusetts
Negative Sentiment: Henry Ford Health filed a lawsuit against CVS alleging a 340B pricing scheme, which could create legal and reputational risk if the claims gain traction. Henry Ford Health sues CVS, alleges 340B pricing scheme

CVS Health Company Profile

(Get Free Report)

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.